Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations.

Cancer research - 15 Dec 2010

Okamoto Kunio, Okamoto Isamu, Okamoto Wataru, Tanaka Kaoru, Takezawa Ken, Kuwata Kiyoko, Yamaguchi Haruka, Nishio Kazuto, Nakagawa Kazuhiko

Abstract excerpt

The molecular mechanism by which epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) induce apoptosis in non-small cell-lung cancer (NSCLC) cells that are positive for activating mutations of the EGFR remains unclear. In this study, we report the effects of the EGFR-TKI gefitinib on expression of the antiapoptotic protein survivin that have functional consequences in EGFR mutation-positive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apoptosis
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Down-Regulation

Share to ErbB Receptors

Share to EGFR gene

Share to Lung Neoplasms

Share to Membrane Proteins

Share to Mutation

Source

Identifiers

PMID: 21159653
DOI: 10.1158/0008-5472.CAN-10-2438

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations.PMID 21159653Read ↗

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.Semantic proximity Read ↗

Trametinib downregulates survivin expression in RB1-positive KRAS-mutant lung adenocarcinoma cells.Semantic proximity Read ↗

Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics.Semantic proximity Read ↗

Survivin mRNA expression in blood as a predictor of the response to EGFR-tyrosine kinase inhibitors and prognosis in patients with non-small cell lung cancer.Semantic proximity Read ↗

Survivin and Tumorigenesis: Molecular Mechanisms and Therapeutic StrategiesSemantic proximity Read ↗

Recent Advances on Small-Molecule Survivin InhibitorsSemantic proximity Read ↗

Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas.Semantic proximity Read ↗

Investigations of survivin: the past, present and futureSemantic proximity Read ↗

Survivin as a Therapeutic Target for the Treatment of Human CancerSemantic proximity Read ↗

Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.Semantic proximity Read ↗

BIM induction of apoptosis triggered by EGFR-sensitive and resistance cell lines of non-small-cell lung cancer.Semantic proximity Read ↗

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.